Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Stock Information for Cidara Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cidara Therapeutics Inc.

Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388
Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules
ROSEN, A LEADING NATIONAL FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.